Syringomyelia

The researchers from Chiropractic Doctors Association of Hong Kong (CDAHK) released their case studies on chronic headaches and neck pain.NEW YORK, Nov. 21, 2022 /PRNewswire/ -- Chiropractors may reduce the number of monthly neck pain and headaches for people who have chronic and complicated type of history, four case studies (1-4) published in 2022 American Journal of Case Reports, found.Chronic headaches involve a painful sensation in any part of the head, ranging from sharp to dull, that may occur with other symptoms at least 15 days per month. Continue Reading Committees of Chiropractic Doctors Association of Hong Kong Chiropractors provide long-term relief from chronic headaches, said Eric Chu, principal investigator of the studies and Chairman of Chiropractic Doctors Association of Hong Kong. "Our recent studies(4-12) have also found that chiropractic may be effective for episodic neck pain and chronic headaches. These studies are successful cases showing that chiropractic is effective specifically for patients who failed with traditional therapy," Chu added."Since chronic headaches with complicated medical history are often more difficult to treat, and the pain medicines used have multiple potential side effects, the results are promising," said Dr. Kingsley Leung, Executive Committee of CDAHK.Multi-model chiropractic therapies involve achieving proper alignment of the spine, which consisted of spinal manipulation, micro-vibration and microcurrent technology to flush out lactic acid and untie deep knots, and robotic spinal decompression for non-surgical intervertebral relief. Non-invasive treatments can plan access to the spine through using a computer-guided robot and traction therapy to safely and effectively elongate and stretch the spine."To achieve a optimal treatment effect of chiropractic therapy, technology is important," Chu said. "The care providers should try their best to use the current technology at each spinal problem.""For patients who do not want to use prescription pain medication, chiropractor offers a hopeful alternative. Treating chronic pain is a multidisciplinary approach, and chiropractic is one of best treatment options that should be considered," Chu said.References 1. Chu EC, Trager RJ, Ng GSN, Shum JSF. Neck pain and Headache Complicated by Persistent Syringomyelia After Foramen Magnum Decompression for Chiari I Malformation: Improvement with Multimodal Chiropractic Therapies. Am J Case Rep. 2022 Oct 31;23:e937826. 2. Chu EC, Trager RJ, Ng GSN, Shum JSF. Neck pain and Headache Complicated by Persistent Syringomyelia After Foramen Magnum Decompression for Chiari I Malformation: Improvement with Multimodal Chiropractic Therapies. Am J Case Rep. 2022 Oct 31;23:e937826. 3. Chu EC, Trager RJ, Tao C, Lee LY. Chiropractic Management of Neck Pain Complicated by Symptomatic Vertebral Artery Stenosis and Dizziness. Am J Case Rep. 2022 Oct 19;23:e937991. 4. Chu EC, Trager RJ, Chen AT. Concurrent Bell's Palsy and Facial Pain Improving with Multimodal Chiropractic Therapy: A Case Report and Literature Review. Am J Case Rep. 2022 Sep 19;23:e937511. 5. Chu EC, Lin AFC (2022) Relief of postural orthostatic tachycardia syndrome with chiropractic rehabilitation Journal of Family Medicine and Primary Care 11: 7. 4006-4009 July. 6. Chu EC. Reducing Cervical Retrolisthesis With Long-Term Monthly Chiropractic Maintenance Care: A Case Report. J Med Cases. 2022 Jul;13(7):359-364. 7. Chu EC, Trager RJ, Shum JSF, Lai CR. Pancoast Tumor Presenting as Neck Pain in the Chiropractic Office: A Case Report and Literature Review. Am J Case Rep. 2022 Jul 7;23:e937052. 8. Chu ECP, Lee LYK. Adjacent segment pathology of the cervical spine: A case report. J Family Med Prim Care. 2022 Feb;11(2):787-789. 9. Eric Chun-Pu Chu (2022) Remission of Headache and Neck Pain Following Chiropractic Manipulative Treatment in a Patient with Neurofibromatosis Chiropractic Journal of Australia 49: 1. 8-18 Feb 10. Chu EC. Preventing the progression of text neck in a young man: A case report. Radiol Case Rep. 2022 Jan 18;17(3):978-982. 11. Chu ECP. Alleviating cervical radiculopathy by manipulative correction of reversed cervical lordosis: 4 years follow-up. J Family Med Prim Care. 2021 Nov;10(11):4303-4306. 12. Chu ECP, Spaska A, Monov D, Kasatkin M, Stroiteleva N. Examining the correlation between salivary cytokine concentrations and CRP in people experiencing social-cognitive stress. Neurol Res. 2022 Oct 5:1-6. 13. Chu ECP. Alleviating cervical radiculopathy by manipulative correction of reversed cervical lordosis: 4 years follow-up. J Family Med Prim Care. 2021 Nov;10(11):4303-4306. This press release was issued through 24-7PressRelease.com. For further information, visit . SOURCE Chiropractic Doctors Association of Hong Kong (CDAHK)

Calgary, Alberta--(News - September 13, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Mr. Thomas Abraham, CA as President, PreCerv Inc. Mr. Abraham has more than 25 years of financing, business development, and governance and risk management experience in a broad range of roles encompassing private equity investment transactions, including sales and distribution of alternative investments, in Toronto, New York, Abu Dhabi, Singapore, Kuala Lumpur, and Glasgow, Scotland. Most recently, Mr. Abraham was the Chief Executive Officer of the Financial Services Professional Board (FSPB), where he was responsible for all business development with local and international bodies, including the oversight of all programs and standards setting activities of FSPB to achieve its mission and objectives. Mr. Abraham is a member of the Institute of Corporate Directors Canada, a Committee member of TC309, Standards Council of Canada, and the Institute of Chartered Accountants of Scotland. He holds a bachelor's degree in Accountancy from London Metropolitan University, U.K. "ACP-01's safety and efficacy pro very impressive, and it is equally promising to combine it NCP to treat conditions of the central and peripheral nervous system," stated Thomas Abraham. "I very much look forward to financing and leading the team that will study, develop and commercialize NCP-01 and ACP-01 in the neuronal field," Mr. Abraham said. "Mr. Abraham's finance and business relationships spans decades in Toronto, New York, the UAE, Singapore, and Malaysia. He is perfectly suited to lead, finance and build PreCerv into a great company focused on treating conditions of the central and peripheral nervous system for Hemostemix shareholders' benefit," stated Thomas Smeenk, CEO. ABOUT HEMOSTEMIX Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Seven studies including 260 ACP-01 recipients define its safety and efficacy pro a treatment for heart diseases such as Dilated and Ischemic Cardiomyopathy, Angina, and diseases of Ischemia such as Critical Limb Ischemia. The Company owns 91 patents across five patent families. For more information, please visit . ABOUT PreCerv Inc. PreCerv Inc. is a wholly owned subsidiary of Hemostemix Inc. PreCerv obtained from Hemostemix a global field of use license to NCP-01 and ACP-01, and its autologous stem cell technologies, to treat conditions of the central and peripheral nervous system, including but not limited to neuropathic pain syndromes; traumatic spinal cord injury, peripheral nerve injury; rare diseases including syringomyelia and age-related macular degeneration (ARMD). NCP-01 are autologous neuronal cell precursors derived from the patient's blood. For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder EM: tsmeenk@hemostemix.com PH: 905-580-4170 Thomas Abraham, President, PreCerv Inc., EM: tabraham@hemostemix.com PH: 647-461-7169 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the lead product ACP-01, NCP-01, and the commercialization of ACP-01 and NCP-01. ‎‎There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory ‎approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the ‎economy generally; consumer ‎interest in Hemostemix's services and products; competition and ‎Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to ‎ fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis mayface; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation ‎affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete;‎ lack of qualified, skilled labour or loss of key individuals; and risks ‎related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to ‎try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and ‎financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a ‎possible national or global recession or depression;the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at . Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit

Calgary, Alberta--(News - June 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has incorporated PreCerv Inc. ("PreCerv"), as a wholly owned subsidiary. PreCerv will obtain from Hemostemix a global field of use license to NCP-01 and its autologous stem cell technologies, to treat conditions of the central and peripheral nervous system, including but not limited to the following: Neuropathic pain syndromes. Traumatic spinal cord injury, chronic brainstem injury, traumatic brain injury, peripheral nerve injury. Rare diseases including: syringomyelia, Charcot-Marie tooth disease, and Guillain-Barre syndrome, Amyotrophic lateral sclerosis (ALS), age-related macular degeneration (ARMD), corneal or eye diseases and retinopathies of any cause. Cerebral stroke "NCP-01 are autologous neuronal cell precursors which, alone or in combination with ACP-01, have the potential to treat many conditions of the central and peripheral nervous system. I want to thank our medical and science teams for translation of that potential into significant studies, and for introductions to the most talented scientists in this field. By originating a field of use license, PreCerv's new management team will fund its studies to unlock NCP's value for the shareholders of Hemostemix," stated Thomas Smeenk, CEO. ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years. The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit . For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder TSmeenk@Hemostemix.com 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the incorporation of PreCerv Inc., the completion of studies of NCP-01, or NCP-01 in combination with ACP-01, a financing of PreCerv Inc. ‎‎There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies as well as management's ‎expectations of anticipated results; Hemostemix's general and administrative costs remaining relatively constant; the receipt of all required regulatory ‎approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the ‎economy generally; consumer ‎interest in Hemostemix's services and products; competition and ‎Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to ‎fund Hemostemix's operations including any research, trials or studies, and the Litigation. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory analyses and the results of such analyses and future clinical ‎trials; ‎litigation and potential litigation that Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation ‎affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete;‎ lack of qualified, skilled labour or loss of key individuals; and risks ‎related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to ‎try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, ‎service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and ‎financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a ‎possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix ‎offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at . Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit